Heartbeam 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Heartbeam reported Q3 2026 net cash used in operating activities of $2.6 million, down 23% from Q2 2026 and 18% from the same quarter in the prior year.
- Q3 2026 operating expenses were $3.5 million, down 32% from Q2 and 35% from Q3 2025; net loss was $3 million, compared with $5.3 million in Q3 2025 and $5 million in Q2.
- For the first 9 months of 2026, operating expenses were $13.3 million versus $15.8 million, net loss was $12.7 million versus $15.7 million, and cash used in operating activities was $9.5 million versus $11.1 million, a decrease of 14%.
- Cash and cash equivalents were $6.1 million at September 30th, 2026, compared with $4.4 million at the end of last year; Heartbeam subsequently raised approximately $4 million of net proceeds through its at-the-market facility, bringing pro forma cash to approximately $10.1 million.
- The ALIGN-HCS study enrolled 132 adults at emergency departments of 2 cardiology centers in Belgrade, Serbia; Heartbeam reported specificity of 81.8% versus 71.4% for the standard 12-lead ECG and sensitivity of 60.2 versus 63.0.
- For STEMI heart attacks, Heartbeam sensitivity was 82.9 versus 83.8 for the standard 12-lead ECG; reader agreement was 0.73 for Heartbeam versus 0.54 for the standard 12-lead ECG.
- Every patient in the study successfully obtained a Heartbeam recording, and the 3D 3-lead and standard 12-lead signals showed the same area under curve.
- Heartbeam completed enrollment ahead of schedule in HEARTSTART-ACS, its largest heart attack assessment study to date using Heartbeam technology, with 486 patients enrolled in Indonesia; data analysis is underway.
- Heartbeam reported clinical experience with more than 600 patients in heart attack assessment across its studies and joined the EU co-funded EXIT-CVD research group, where it will lead the HEART-TRACK study.
- Heartbeam's dataset includes more than 168 ECGs for heart attack training and more than 2,100 Heartbeam device recordings for testing; its arrhythmia AI model is complete, while the heart attack assessment AI model remains under development.
- Early internal AI analysis found sensitivity about 12 percentage points higher across all heart attacks and 19 percentage points higher for non-ST elevation heart attacks than physicians reading the same recordings, at similar specificity; management said these results are early, internal, not yet peer-reviewed, and the AI remains in beta, investigational, and not FDA cleared.
- Heartbeam's initial atrial flutter algorithm showed 97% accuracy compared with electrophysiology study in 600 recordings using standard 12-lead ECGs; the work was presented as an abstract at ECHA 2026 and published in Europace, and the full manuscript was accepted by Canadian Journal of Cardiology.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
and welcome to the HeartBeam Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on the call today and webcast may include predictions, estimates, and other information that may be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.
Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision of these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wire this afternoon and is available in the Investor Relations section of our company's website, heartbeam.com. Your hosts today, Richard Ferrari, Executive Chairman, Branislav Vajdic, Founder and President, and Tim Cruickshank, Chief Financial Officer, will present results of operations for the third quarter ended September 30, 2026. At this time, I would like to turn the conference over to Richard Ferrari.
Thank you, and thanks to all of you that have dialed into the conference call. Let me just walk you through the agenda very briefly. We're going to give you the progress on our key strategic initiatives. We'll bring you updates regarding our cardiac platform and our heart attack detection, which is an incredible milestone that we've achieved this particular quarter. Finally, we'll close out with the financials. Next slide. Progress on the key strategic priorities. I think many of you that have been following the company will remember that in July of this year, we outlined our plan going forward, and we organized the focus on our core strategic priorities, which are shown on this particular slide.
That was MI detection, working closely with the FDA, working on reimbursement, enhancing the long-term value of the company through AI and the other technological initiatives, and on the financial side, cost efficiency and tight controls with respect to running the company. When you look at heart attack detection, I have to say that in the last 90 days, Q3 was a fabulous quarter for achievement, and I think that's a testament we have, and the shift to the priorities that I have already mentioned. When you look at those achievements, these milestones are, for a small company, quite significant. Getting Breakthrough Device designation, something we were really going after, really wanted to count on. Just to give you sort of a reference point, the FDA, on an average over the last five, six, seven years, only hands out about 164 of these designations.
It is proof statement that the technology and the opportunity to enhance patients' lives is significant with respect to HeartBeam. That also enabled us to get enrolled, if you will, into their TAP program. The TAP program is also quite significant because it enables us to have faster turnaround with our communications with the FDA. It also opens up CMS and payers so that we can have discussions with them regarding reimbursement and what are the needs that they need to see in our clinical trial to establish reimbursement.
Then I think many of you may know that we had our publication, our presentation at the TCT meeting at the end of October, which again, in our perspective, is the first study, it was 132 patients, first study to really look at, in an emergency room setting, a comparison between the gold standard of the last 50 years, 12-lead EKG, and our handheld device for MI detection. Those results, Branislav Vajdic will touch on a little bit later in this presentation, which were significant. I do not know that we have said this before. We did tell you that we were working hard with the FDA with respect to whether or not we would have a 510(k) or a De Novo path. We have a 510(k) path. That is significant because it streamlines our timelines with respect to ultimately getting approval to launch our MI initiatives.
Then lastly, again, because of the path and the designation, Breakthrough Device designation, we are in constant communications actually with the FDA on our pivotal study. We have had a number of interactions with them. We are very confident in how we have structured that pivotal trial, and we are also very confident that we will getting approval with FDA very shortly on launching that trial and starting it, potentially this year, but certainly in Q1 of 2027. On the reimbursement path, we have a reimbursement consultant we are working with, and as I mentioned to you, we will be in discussions with CMS payers, seeing what it is that they need to have from us with respect to the clinical trial results or secondary endpoints that we might put in there that would enable them to go ahead and issue a DRG code for the HeartBeam technology.
We are pleased with the progress we are making there. On the long-term value and the AI side, we are going to touch on this in a minute, the market opportunity here, which you will hear me speak about more, is just gigantic actually. The beauty to what HeartBeam's technology is that we can embed this technology in several different form factors, which I will also review. The real benefit of HeartBeam is on its 3D technology. You have heard me mention this before, that is the technology we have is simply the best signal capturing and interrogation product that exists. That is important because we are moving into utilizing AI to help further streamline the information to physicians, and the richer data one has, the more valuable the information is. So we are really excited, and Branislav Vajdic will touch on this, about our AI initiatives.
As Tim will touch on later as well, is what we have been doing in controlling the cost and managing our cash appropriately. Next slide. I am going to walk us through the HeartBeam cardiac platform for you. Next slide. This slide really depicts, I think, the essence of what it is HeartBeam is dedicated to do. Patient delay in terms of getting to the hospital from the time that they have the symptom is the number one cause of death, and there is simply no device that a patient can have with them at their home, on vacation, traveling, that would enable them to determine whether or not they are having a heart attack. If you look at the data on the left-hand side of that page, it is very, very revealing as to the damage that delay causes. Every 30-minute delay, 8.7% heart failure risk.
This is obviously a big problem for the healthcare system. People that have congestive heart failure, they are repeat flyers in and out of the hospital at huge costs in terms of care, and a 7.5% one-year mortality. Again, at the bottom, very costly approach to delays. We are very, very excited about, quote, "our initial results," as you will see from the ALIGN study and what that means, and the fact that we are really just improving how rapidly a patient has a symptom and can get to the hospital. Again, I will just reinforce this. Currently, there is no home ECG tool that reliably detects heart attacks. The importance of getting to the hospital is paramount. Next slide. When you look at the core technology platform, I have said this a few times this morning, but I will say it again, the size of the TAM, the cardiac platform opportunity that we have is simply one of the largest in the entire healthcare industry, a $40 billion opportunity affecting 50 million plus patients.
When you squeeze down on the specifics to heart attack detection, those patients that would be at risk, that is 20 plus million people. Once again, you could see the importance of having a device that was with you at all times, specifically if you had already had balloon angioplasty, cardiac surgery, atrial fibrillation procedure, coronary stents, any predetermined risks related to your genetics in terms of heart health.
Our goal is to close that gap between symptom onset and care by giving patients something that they can have with them and get an immediate response. It is a first-of-a-kind portable cable-free EKG device. It provides a clinical-grade report to a bank of cardiologists that read that information and then provide notification to the patient. On top of that, we have 25 issued patents worldwide incorporating our proprietary technology. Once again, the signal capturing and the ability to integrate the signal for us, the EKG signal, just opens up tremendous opportunities for us going forward to further and further enhance types of information we are providing to the physicians, the cardiologists, as well as to the patient themselves. Next slide. I think you have also heard us talk about the fact that the technology is already proven. We have already built this technology.
We have utilized it in a number of clinical trials. There's nothing more for us to build with respect to the signal capturing and the hardware. All we're doing now is enhancing through AI initiatives. Because of that, we're capable of taking that technology and putting it into different form factors depending upon the application. In this particular slide, you see the HeartBeam card, and that will be an item that someone carries with them. As you know, it's just roughly the size of a credit card. It will allow them to determine whether or not they have AFib or whether or not they're having a heart attack. The patch is a different form factor and addresses a different aspect of the market. It's targeted more for the inpatient step-down units where the nurses are circulating and you may have an at-risk cardiac patient staying overnight or two.
It'd be great if you had a patch on there where they said, "Gee, listen, why don't you put two fingers up and let's take a reading and see how you're doing?" Of course, when they're discharged, we want them to go away either with the card or the patch, again, depending upon the specifics of that particular patient. Then we have what we call the HeartBeam remote unit, and this is, again, same technology, but it's something that we're looking at in terms of outside the U.S., in more remote locations where towns or villages or what have you, who don't have tremendous access to the new and greatest technology, would in fact be able to offer something to the people of that particular area that would provide, again, the type of information that's so critically important to their cardiac health. Next slide, please. The heart attack detection and the milestones that we've achieved, now we've touched on this, but this is the roadmap going forward.
When you think about HeartBeam, this is the way that you really should value the company, is these next series of steps. We're really proud of the team that we've got because they execute flawlessly in Q3, and they will execute flawlessly, in my opinion, on these next series of milestones. We already know positive pilot study data, and Branislav Vajdic is going to touch on that. We have agreement with the FDA on 510(k), and we indicated to you previously that we thought that's the way it would go. We are in constant communication with them regarding the pivotal study, mostly regarding the statistical model required, which drives the number of patients.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 0 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
